News in Brief

Boehringer Ingelheim joins SCRS as Global Impact Partner

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/g-stockstudio)
(Image: Getty/g-stockstudio)

Related tags: Boehringer ingelheim, Clinical trial

Boehringer Ingelheim has joined the Society for Clinical Research Sites as a Global Impact Partner (GIP) to help identify new approaches to working with sites.

SCRS​ is a global trade organization representing more than 9,000 clinical research sites in 47 countries.

The organization’s GIP Program provides a platform for sponsors, contract research organizations (CROs) and vendors to engage with SCRS and its members.

We look forward to working with SCRS to identify innovative approaches to working with sites as partners and to collaborate with other industry leaders to advance the clinical trial process,​” said Theresa Devins, senior associate director for Boehringer Ingelheim in a press release.

The Germany-based pharmaceutical company also recently joined​ with leaders at the Northwell Health’s Feinstein Institute for Medical research and the US Food and Drug Administration (FDA) to discuss the challenges and opportunities to increase patient diversity in clinical trials.

The company is actively collaborating with a variety of partners to help increase patient diversity in clinical trials, Boehringer Ingelheim senior vice president of medicine and regulatory affairs Sabine Luik, MD, told us in December.

Related topics: Clinical Development

Related news

Follow us

Products

View more

Webinars